CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

An Evaluation Of Efficacy And Safety Of Drugs In Patients Of Rheumatoid Arthritis And Their Impact On Quality Of Life

Author: 
Dr. Mayur M. Sisodiya, Dr. Anuradha Gandhi, Dr Prakruti Patel, Dr Vishnu Sharma and Dr Mira Desai
Subject Area: 
Health Sciences
Abstract: 

Aims: To evaluate efficacy and safety of drugs in patients of rheumatoid arthritis (RA) and their impact on quality of life. Materials and Methods: Newly diagnosed patients of RA were included in the study [Group A=Methotrexate (7.5 to 25 mg) orally + Hydroxychloroquine (200 mg) orally& Group B =Methotrexate (7.5 to 25 mg) orally + Hydroxychloroquine (200 mg) orally + Prednisolone (1 mg/kg/day and then tapered to maintenance dose 7.5 mg/day) orally] and followed up for a period of 6 months after enrolment. Efficacy of drugs was assessed using Disability Assessment Score 28 (DAS 28) and Quality of life was measured with Modified Health Assessment Questionnaire (MHAQ).The data was recorded in Microsoft Excel Worksheet version 2007 and statistical evaluation was done using ANNOVA test and unpaired t-test and P<0.05 was considered to be statistically significant. Result: Total 82 patients were included and divided in group [A (n=47) and B (n=35)]. In group A & B, there was significant reduction (P<0.001) in DAS28 at 2nd follow up as compared to baseline. In group B, DAS28 was significantly reduced at 1st follow up (P<0.05). Mean difference between group A & B was non-significant. In group A, total MHAQ was significantly change (P<0.001) at 2nd follow up as compared to baseline. In group B, the groups. Conclusion: MHAQ score was significantly reduced (P<0.001) at 1st follow up and at 2nd follow upas compared to baseline. Significant reduction (P<0.001) in MHAQ observed in both the group at 2nd follow up as compared to 1st follow up. In group B, there was strong correlation (r value=0.7) between DAS28 & MHAQ. Adverse drug reaction observed were mild in severity in both DMARDs decrease the severity of symptoms in RA patients over a period of time but symptomatic improvement is seen earlier in combination of DMARDs (methotrexate and hydroxychloroquine) plus prednisolone therapy.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran